Anti-inflammatory tripeptide
The C-terminal tripeptide of alpha-MSH (Lys-Pro-Val), studied in the preclinical literature for its anti-inflammatory and gut-mucosal activity. Supplied as a 10 mg vial, or as a pre-filled research pen in 10 mg, 20 mg and 30 mg.
| Compound | KPV (Lys-Pro-Val) |
| Research category | Regenerative Research |
| Available sizes | Vial: 10 mg · Pen: 10 mg, 20 mg, 30 mg |
| Pricing | Vial £33 · Pen £68 / £105 / £125. Prices exclude postage. |
| Format | Lyophilised powder in sealed vial |
| Purity | >99% by HPLC (Janoshik Analytical, batch-verified) |
| Intended use | In-vitro laboratory research only. Not for human consumption. |
Reference data drawn from public databases (PubChem, UniProt) and peer-reviewed literature. For research and laboratory characterisation only.
| Compound class | Tripeptide (alpha-MSH C-terminal fragment) |
| Molecular formula | C16H30N4O4 |
| Molecular weight | 342.44 g/mol |
| CAS Registry Number | 67727-97-3 |
| Amino acid sequence | Lys-Pro-Val (KPV) |
| Receptor / mechanism | Anti-inflammatory signalling; melanocortin-pathway derived. Refer to primary literature. |
| Reported half-life | Short; small tripeptide rapidly cleared once reconstituted. |
| Solubility | Lyophilised powder reconstitutes in bacteriostatic water for laboratory use. |
| Storage (lyophilised) | Stable at 2–8 °C lyophilised for 18+ months. |
| Storage (reconstituted) | Reconstituted: store at 2–8 °C, use within 14 days. |
| Clinical / regulatory status | Research compound. Not an approved medicine in the UK. |
KPV is the Lys-Pro-Val tripeptide that forms the C-terminal sequence of the melanocortin alpha-MSH. It is characterised in the preclinical literature (for example Dalmasso et al. 2008 and Kannengiesser et al. 2008) for anti-inflammatory activity in intestinal-epithelial and colitis research models, retaining part of alpha-MSH's activity in a much smaller, more stable fragment. Supplied for in-vitro research use only.
The above describes how this compound is characterised in the published peer-reviewed literature. It is not a claim about effects in humans.
KPV is supplied as a lyophilised (freeze-dried) powder in a sealed glass vial. For laboratory reconstitution, add the desired volume of diluent (typically bacteriostatic water) slowly down the side wall of the vial. Swirl gently until fully dissolved - do not vortex or shake. Store reconstituted solutions at 2–8 °C and use within 4–6 weeks.
Use our Reconstitution Volume Calculator to compute the resulting mg/ml concentration.
Every batch of KPV we supply is independently HPLC-verified by Janoshik Analytical. Where a Janoshik report has been issued for the current batch it is supplied with the order and carries a unique verification key that can be authenticated against Janoshik's records. Reported purity is consistently above 99%.
Latest Janoshik report for KPV 10mg · task #231380 · analysed 28 Sep 2026
This report is for the batch, not the size. Janoshik’s HPLC test measures what the compound is and how pure it is, and its quantification confirms the amount in the vial tested. Every size of KPV is filled from the same tested batch, so this 10mg report covers 20mg and 30mg as well. The report supplied with your order carries a verification key you can check on Janoshik’s own site.
| Purity | 99.270% |
| Measured content | 11.09 mg |
| Batch | L77KPV2612 |
| Verification key | TCNLP1DN3XU3 |
Researchers working with KPV often work alongside the following compounds in the preclinical literature: